13 citations
,
December 2021 in “Journal of Cellular and Molecular Medicine” This case report observed that treatment with human placental mesenchymal stromal cell-derived exosome-enriched extracellular vesicles may improve symptoms of chronic cutaneous graft-versus-host disease, including hyperpigmentation and skin ulcers, in a patient resistant to conventional therapies.
1 citations
,
November 2024 in “Blood” This study found that inhibiting the PI3Kδ enzyme in murine models of cutaneous chronic graft-versus-host disease (cGVHD) reduced skin scores and fibrosis, prevented pathogenic lymphoid structures, and improved survival, suggesting it as a promising therapeutic approach to address the disease's hypoxic pathophysiology.
17 citations
,
June 2016 in “Croatian Medical Journal” In this study, vitiligo and alopecia areata were more common among patients with chronic graft-vs-host disease than previously reported, linked to higher NIH skin scores and greater immunosuppressive treatment.
June 2026 in “Indian Journal of Case Reports” This source reports a rare case of a 10-year-old child developing periorbital milia as an unusual cutaneous manifestation of chronic graft-versus-host disease following allogeneic stem cell transplantation, suggesting that immune-mediated epidermal disruption may lead to milia formation.
7 citations
,
March 2018 in “Journal of The American Academy of Dermatology” This study found that pediatric HSCT recipients, especially those with chronic graft-versus-host disease, are at risk for developing various nonmalignant late cutaneous changes such as vitiligo, psoriasis, alopecia, and nail changes.